Generated June 24, 2026 at 8:34 PM ET
· Covers June 24 trading day
· 10 of 184 ready 8-Ks selected
· AI-assisted overview
Aditxt (ADTX) faces trading suspension after Nasdaq denied its listing request, while GD Culture Group (GDC) raised $5.45M in a direct offering but received a bid price deficiency notice. Positive regulatory news included FDA approval of Ionis' (IONS) TRYNGOLZA for severe hypertriglyceridemia and FDA alignment for Cognition Therapeutics' (CGTX) pivotal trial design. Barnes & Noble Education (BNED) reported preliminary FY2026 net income of $15-18M versus a prior loss and initiated a dividend. Colony Bankcorp (CBAN) agreed to acquire First Reliance Bancshares, and CEA Industries (BNC) appointed three YZi Labs directors and formed a CEO search committee.
leadership
positive
materiality 0.85
June 24, 2026, 5:29 PM ET
CEA Industries (BNC) appoints three YZi Labs directors, ends proxy contest, forms CEO search
- YZi Labs ends consent solicitation; Board expands to six, appoints Ella Zhang, Alex Odagiu, Matthew Roszak.
- Alex Odagiu named Interim President; CEO Search Committee formed to find new CEO by Aug 31, 2026 or annual meeting.
- Mutual release of claims; YZi Labs agrees to standstill and voting commitments through 2029.
regulatory
negative
materiality 0.95
June 24, 2026, 11:36 AM ET
Nasdaq Panel denies Aditxt listing; trading suspended June 25, 2026
- Nasdaq Hearings Panel denied Aditxt's request to continue listing; trading suspended at open on June 25, 2026.
- Company non-compliant with Bid Price Rule ($1.00 min) and Equity Rule ($2.5M min; reported $(35.2M) equity).
- Panel skeptical of Ignite valuation jump from $35M to $150M in months; company has completed 7 reverse stock splits.
M&A
positive
materiality 0.85
June 24, 2026, 5:00 PM ET
Colony Bankcorp to acquire First Reliance Bancshares for ~$163M, 20% cash/80% stock
- Deal valued at ~$163M; FSRL shareholders can elect $19.75 cash or 0.94 Colony shares per share.
- Expected Q4 2026 close; pro forma ~$5B assets, $4.0B deposits, and $3.2B loans.
- Transaction immediately accretive to Colony EPS excluding one-time merger costs.
IONS
IONIS PHARMACEUTICALS INC
regulatory
positive
materiality 0.85
June 24, 2026, 3:48 PM ET
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
- FDA approved TRYNGOLZA (olezarsen) as adjunct to diet to reduce triglycerides and risk of acute pancreatitis in adults with sHTG (TG ≥500 mg/dL).
- Phase 3 CORE/CORE2: fasting TG lowered up to 72% vs placebo at 6 months; acute pancreatitis events reduced up to 91%.
- 86% of patients achieved TG <500 mg/dL at 12 months; NNT to prevent one acute pancreatitis: 20 overall, 4 in highest-risk subgroup.
—
Prologis, L.P.
M&A
negative
materiality 0.80
June 24, 2026, 6:19 AM ET
Prologis reveals all-share bid for SEGRO; board rejects, urges engagement
- Prologis proposed an all-share acquisition of SEGRO plc on June 16, 2026.
- SEGRO board unanimously rejected the proposal on June 23, 2026.
- Prologis urges SEGRO shareholders to press the board to engage.
ALSAF
Alpha Star Acquisition Corp
M&A
positive
materiality 0.80
June 24, 2026, 4:41 PM ET
Alpha Star shareholders approve business combination with XDATA; only 46 shares redeemed
- All seven proposals passed with near-unanimous support from over 3.2M shares voted (99.36% of outstanding).
- Only 46 ordinary shares tendered for redemption, indicating strong shareholder backing for the deal.
- Business Combination Agreement with XDATA Group and reincorporation merger approved; closing expected soon.
CGTX
COGNITION THERAPEUTICS INC
regulatory
positive
materiality 0.80
June 24, 2026, 7:39 AM ET
Cognition Therapeutics receives FDA alignment on pivotal trial design for zervimesine in DLB psychosis
- FDA agreed that DLB psychosis is an approvable outcome; key aspects of Phase 3 trial design aligned.
- Phase 3 study expected to start mid-2027; enrollment of DLB patients with psychosis, randomized to 100 mg zervimesine or placebo for 9 months.
- Company to use NPI as novel primary endpoint; FDA will collaborate on analytical and statistical details.
CODI
Compass Diversified Holdings
litigation
positive
materiality 0.75
June 24, 2026, 4:15 PM ET
CODI settles Lugano bankruptcy claims; expects recovery from inventory, tax refunds, insurance and litigation proceeds
- CODI to receive 34.79% of net proceeds from Lugano inventory sale, tax refunds, and theft insurance; 45% from certain third-party litigation; 25% from other litigation.
- Settlement contingent on creditor approval and bankruptcy court confirmation of Lugano Plan of Liquidation; no assurance of effectiveness or timing.
- CODI and related parties receive releases from all claims by Lugano estate; CODI retains residual claim but expects no material recovery from it.
BNED
Barnes & Noble Education, Inc.
earnings
positive
materiality 0.85
June 24, 2026, 4:24 PM ET
BNED preliminary FY2026 net income $15-18M vs $65.8M loss; Adj EBITDA $75-77M, initiates $0.08 dividend
- Revenue $1.71-1.72B (+6.2-6.8% YoY); First Day program revenue +27-28% to ~$760M.
- Net income $15-18M vs prior year net loss of $65.8M; Adjusted EBITDA $75-77M (+26-30% YoY).
- Total debt reduced to $71.0M from $103.1M; net debt $62.6M, a 33% YoY decrease.
other material
negative
materiality 0.90
June 24, 2026, 5:00 PM ET
GD Culture Group Raises $5.45M in Registered Direct Offering and Receives Nasdaq Bid Price Deficiency Notice
- Sold 259,301,306 shares at $0.021 per share for gross proceeds of approximately $5.45 million.
- Received Nasdaq notification on June 22, 2026 that minimum bid price below $1.00 for 30 consecutive days.
- Has until December 21, 2026 to regain compliance; may consider reverse stock split.